Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 26;72(8):1467-1474.
doi: 10.1093/cid/ciaa1249.

Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?

Affiliations
Review

Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?

Chanu Rhee et al. Clin Infect Dis. .

Abstract

Defining the duration of infectivity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has major implications for public health and infection control practice in healthcare facilities. Early in the pandemic, most hospitals required 2 negative RT-PCR tests before discontinuing isolation in patients with Covid-19. Many patients, however, have persistently positive RT-PCR tests for weeks to months following clinical recovery, and multiple studies now indicate that these generally do not reflect replication-competent virus. SARS-CoV-2 appears to be most contagious around the time of symptom onset, and infectivity rapidly decreases thereafter to near-zero after about 10 days in mild-moderately ill patients and 15 days in severely-critically ill and immunocompromised patients. The longest interval associated with replication-competent virus thus far is 20 days from symptom onset. This review summarizes evidence-to-date on the duration of infectivity of SARS-CoV-2, and how this has informed evolving public health recommendations on when it is safe to discontinue isolation precautions.

Keywords: COVID-19; SARS-CoV-2; isolation; transmission-based precautions.

PubMed Disclaimer

Comment in

  • Reply to Cimolai.
    Rhee C, Kanjilal S, Baker M, Klompas M. Rhee C, et al. Clin Infect Dis. 2021 Oct 5;73(7):e1788-e1789. doi: 10.1093/cid/ciaa1634. Clin Infect Dis. 2021. PMID: 33104178 Free PMC article. No abstract available.
  • Not All Viral Culture Approaches Are Equal.
    Cimolai N. Cimolai N. Clin Infect Dis. 2021 Oct 5;73(7):e1787-e1788. doi: 10.1093/cid/ciaa1632. Clin Infect Dis. 2021. PMID: 33104181 No abstract available.

Publication types